

ISOLAGEN INC
Form 8-K
August 26, 2004

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

August 26, 2004

Date of Report (date of Earliest Event Reported)

ISOLAGEN, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE

(State or Other Jurisdiction of
Incorporation or Organization)

001-31564

(Commission File No.)

87-0458888

(I.R.S. Employer Identification
No.)

2500 Wilcrest, 5th Floor, Houston, Texas 77042
(Address of principal executive offices and zip code)

(713) 780-4754

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed from last report)

Item 8.01.

Other Events.

On August 26, 2004, the Company issued a press release announcing the Company has been granted EU patent EP0845963 entitled "The Use of Autologous Dermal Fibroblasts for the Repair of Skin and Soft Tissue Defects" covering the Company's proprietary Isolagen Process in 17 European countries. The reader is advised to read the press release in its entirety.

[THE SIGNATURE PAGE FOLLOWS.]

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: August 26, 2004

By: /s/ Jeffrey W. Tomz
Chief Financial Officer